분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2015-01-07 00:57:28 , Hit : 964
 Mass. developer of messenger RNA drugs gets $450M funding boost

By Robert WeismanGlobe Staff  January 05, 2015

Moderna Therapeutics, which specializes in developing drugs in the messenger RNA technology field, raised $450 million from several investors. The Cambridge, Mass.-based firm said the money will enable it to increase its staff, expand its workplace and advance its lead drug candidates into clinical trials.

Cambridge, MA 1/28/14 Senior research associate Summar Siddiqui at work at Moderna. Moderna Pharma researchers working on a messenger RNA drug platform, for a story on RNA therapeutics. It holds the promise of revolutionizing the discovery of new medicines by turning genes on and off. (Michele McDonald for the Boston Globe)
Michele McDonald for The Boston Globe

Senior research associate Summar Siddiqui at work at Moderna last year.
By Robert WeismanGlobe Staff  January 05, 2015

Moderna Therapeutics Inc., a three-year-old Cambridge company working on 45 experimental drugs in the emerging field of messenger RNA technology, said Monday that it has landed $450 million in new financing — one of the largest private biotech investments ever.

The money will enable Moderna to add 100 employees to its 145-person workforce over the coming year, expand into larger quarters around Kendall Square, and push the first batch of its drug candidates into clinical trials during the next two years, the company said.


Moderna’s funding round includes the institutional giants Viking Global Investors, Invus, RA Capital Management, and Wellington Management Co., as well as a pair of biopharma companies that collaborate with Moderna, AstraZeneca PLC and Alexion Pharmaceuticals Inc.

Created by the Cambridge venture capital firm Flagship Ventures, which remains its largest investor, Moderna has developed an RNA messenger technology using genetic information to specify the amino-acid sequence of proteins. Among other things, the approach might allow scientists to inject an RNA “instruction set” into damaged heart tissue to create a stem cell-stimulating protein that would regrow tissue after a heart attack.

“We are advancing a new technology, and we are inventing a new business model,” said Moderna’s chief executive, Stephane Bancel.

Under its business model, Moderna will manage a portfolio of experimental medicines, developing some on its own and others in alliance with larger partners. The Anglo-Swedish drug maker AstraZeneca is collaborating with Moderna on 29 drug programs, including the one involving heart tissue. Alexion is working with Moderna on another seven programs. Moderna is developing nine drugs on its own.

Bancel said his “crazy goal” is to use the messenger RNA technology to bring 100 new drugs to patients within the coming decade. Thus far, however, the Cambridge biotech startup has no approved drugs and all of its experimental programs are preclinical.

That hasn’t discouraged investors such as RA Capital Management, a Boston crossover fund that invests in health care-focused private and public companies. Moderna’s approach has the potential to generate drugs to treat multiple diseases and conditions, ranging from heart failure to cancers to enzyme deficiencies, said RA Capital managing partner Peter Kolchinsky.

“Moderna has more variations of what it can do with its technology than any other company I’ve ever seen,” Kolchinsky said. “When we mapped out the disease areas that might be impacted by Moderna’s technology, we realized that we just had to be in the middle of this. If we succeed, this industry isn’t going to be the same in five years.”

The financing round brings to $950 million the total funding raised by Moderna since its founding in 2011. Bancel said Moderna now has $800 million in cash on hand to expand and move its research and development programs forward.

In addition to AstraZeneca and Alexion, it has a partnership with the Defense Advanced Research Projects Agency, the Pentagon’s research arm. Bancel said his company has no plans to be acquired or to go public in the coming year.

“The plan is to invest more in the technology and hire more people to prove the science,” he said. “We are playing a very long game. It takes many years and a lot of time and cash to improve the performance of a new technology. We believe we are in the beginning of a 20-year performance journey. We want to bring a lot of new medicines to patients.”


Robert Weisman can be reached at robert.weisman@globe.com. Follow him on Twitter @GlobeRobW.







1007   US pharmacy deals could cut costs of AbbVie and Gilead's HCV treatments  이성욱 2015/01/08 1664
1006   Janssen, Isis Pharma Ink Up-to-$835M Antisense Agreement  이성욱 2015/01/07 1179
1005   CVS Gives Preferred Status to Gilead’s Hepatitis C Drugs  이성욱 2015/01/07 1302
  Mass. developer of messenger RNA drugs gets $450M funding boost  이성욱 2015/01/07 964
1003   아직도 풀리지 않은 STAP줄기세포 미스터리  이성욱 2015/01/06 1009
1002   에볼라 확산원인에 대한 새로운 주장  이성욱 2015/01/06 1113
1001   Scientists explain how stem cells and 'bad luck' cause cancer  이성욱 2015/01/06 925
1000   자가 항체에 의한 전신 홍반성 루프스 발생 기작  이성욱 2015/01/05 1551
999   줄기세포로 만든 초기 난자와 정자  이성욱 2014/12/31 1146
998   텔로머레이즈 기반 유전자 요법으로 심장마비 치료  이성욱 2014/12/24 1661
997   일본의 검증팀 STAP 세포 재현 포기, 오보카타 사임  이성욱 2014/12/23 1074
996   아수라장 속에서 탄생한 생명  이성욱 2014/12/17 1236
995   암 생존율을 높일 수 있는 면역세포  이성욱 2014/12/16 1091
994   FDA approves 9-valent HPV vaccine for certain cancers  이성욱 2014/12/12 1141
993   C형 간염 치료에서 비용 효율성을 보인 시메프레비르(simeprevir) 기반 요법  이성욱 2014/12/11 1710
992   Y 염색체 상실을 초래할 수 있는 흡연  이성욱 2014/12/10 1338
991   술의 역사: 영장류가 진화한 것은 알코올 섭취능력 때문?  이성욱 2014/12/04 1266
990   혈우병 환자들에게 안전성과 효과를 입증한 유전자 요법  이성욱 2014/11/27 1613
989   EMA panel recommends approval of DAA regimen for patients with HCV  이성욱 2014/11/26 1281
988   AMD를 치료하는데 사용될 수 있는 HIV/AIDS 약물들  이성욱 2014/11/26 1390

[이전 10개] [1]..[11][12][13] 14 [15][16][17][18][19][20]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN